EPHA2 and pancreatic neoplasm: These data clearly identify targefrinas a potent EphA2-LBD binding agent with antagonistic activity, whiletargefrin-dimer displayed a similar potent affinity for the isolatedEphA2-LBD, but it also displayed potent EphA2 degradation activityin pancreatic cancer cells.